9-4-2014

Post-zygotic and inter-individual structural genetic variation in a presumptive enhancer element of the locus between the IL10RB and IFNAR1 genes

Hamid Reza Razzaghian
Lars A. Forsberg
Kancherla Reddy Prakash
Szymon Przerada
Hanna Paprocka

See next page for additional authors

Follow this and additional works at: https://hsrcc.himmelfarb.gwu.edu/smhs_medicine_rheum_facpubs

Recommended Citation
Post-Zygotic and Inter-Individual Structural Genetic Variation in a Presumptive Enhancer Element of the Locus between the IL10Rβ and IFNAR1 Genes

Hamid Reza Razzaghian1*, Lars A. Forsberg1*, Kancherla Reddy Prakash1, Szymon Przerada1, Hanna Paprocka1, Anna Zywicka1, Maxwell P. Westerman2, Nancy L. Pedersen3, Terrance P. O’Hanlon4, Lisa G. Rider5, Frederick W. Miller6, Ewa Srupek5, Michal Jankowski7, Wojciech Zegarski5, Arkadiusz Piotrowski6, Devin Absher7, Jan P. Dumanski1*

1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, 2Hematology Research, Mount Sinai Hospital Medical Center, Chicago, Illinois, United States of America, 3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, 4Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health Clinical Research Center, Bethesda, Maryland, United States of America, 5Surgical Oncology Clinic, Collegium Medicum, Oncology Center, Nicolaus Copernicus University, Bydgoszcz, Poland, 6Department of Biology and Pharmaceutical Botany, Medical University of Gdańsk, Gdańsk, Poland, 7HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, United States of America

Citation: Razzaghian HR, Forsberg LA, Prakash KR, Przerada S, Paprocka H, et al. (2013) Post-Zygotic and Inter-Individual Structural Genetic Variation in a Presumptive Enhancer Element of the Locus between the IL10Rβ and IFNAR1 Genes. PLoS ONE 8(9): e67752. doi:10.1371/journal.pone.0067752

Editor: Tatjana Adamovic, Karolinska Institutet, Sweden

Received January 29, 2013; Accepted May 21, 2013; Published September 4, 2013

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: This study was sponsored by grants from the Ellison Medical Foundation (JPD and DA), the Swedish Cancer Society, the Swedish Research Council, Swedish Heart-Lung Foundation, and the Science for Life Laboratory-Uppsala (JPD). AP acknowledges FOCUS 4/2008 and FOCUS 4/2009 grants from the Foundation for Polish Science. Genotyping was performed in part by the SNP&SEQ Technology Platform, which is supported by Uppsala University, Uppsala University Hospital, the Science for Life Laboratory–Uppsala, and the Swedish Research Council (contracts 80576801 and 70374401). This study was also supported in part by the intramural research program of the National Institute of Environmental Health Sciences, the National Institute of Health, Bethesda, Maryland, United States of America. SATSA study was supported in part by grants from the NIH (AG 04563, AG10175) and the Swedish Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jan.dumanski@igp.uu.se

These authors contributed equally to this work.

Abstract

Although historically considered as junk-DNA, tandemly repeated sequence motifs can affect human phenotype. For example, variable number tandem repeats (VNTR) with embedded enhancers have been shown to regulate gene transcription. The post-zygotic variation is the presence of genetically distinct populations of cells in an individual derived from a single zygote, and this is an understudied aspect of genome biology. We report somatically variable VNTR with sequence properties of an enhancer, located upstream of IFNAR1. Initially, SNP genotyping of 63 monozygotic twin pairs and multiple tissues from 21 breast cancer patients suggested a frequent post-zygotic mosaicism. The VNTR displayed a repeated 32 bp core motif in the center of the repeat, which was flanked by similar variable motifs. A total of 14 alleles were characterized based on combinations of segments, which showed post-zygotic and inter-individual variation, with up to 6 alleles in a single subject. Somatic variation occurred in ~24% of cases. In this hypervariable region, we found a clustering of transcription factor binding sites with strong sequence similarity to mouse Foxg1 transcription factor binding motif. This study describes a VNTR with sequence properties of an enhancer that displays post-zygotic and inter-individual genetic variation. This element is within a locus containing four related cytokine receptors: IFNAR2, IL10Rβ, IFNAR1 and IFNγR2, and we hypothesize that it might function in transcriptional regulation of several genes in this cluster. Our findings add another level of complexity to the variation among VNTR-based enhancers. Further work may unveil the normal function of this VNTR in transcriptional control and its possible involvement in diseases connected with these receptors, such as autoimmune conditions and cancer.

Introduction

The Encyclopedia of DNA Elements (ENCODE) project has recently characterized regions of transcription, transcription factor association, and chromatin structure suggesting biochemical functions for up to 80% of the human genome [1]. Repetitive DNA sequences with shorter repeat-motifs fall into two main categories; interspersed repeats and variable number tandem repeats (VNTR). The interspersed repeats are remnants of transposons and are more abundant than VNTRs [2]. In VNTRs, repeat-motifs are positioned right next to each other. They are called microsatellites, with repeat-motifs <10 bp, and minisatel- lites with repeats ≥10 bp. The VNTRs are sometimes extremely variable with de novo mutation rates up to 10−3 per locus per cell division and their mutation rates therefore typically exceed mutation rates of CNVs and SNPs by factor 10 to 100,000 [2]. Although historically considered as part of junk-DNA, VNTRs can affect human phenotype. For example, disorders such as Fragile X syndrome [3], spinobulbar muscular atrophy [4], and Huntington disease [5] have all been associated with specific
unstable repeat expansions within genes (reviewed in [2,6,7]). VNTRs outside of genes have also been found to influence gene expression and phenotype. For instance, it is established that variants of a repeat in the promoter of the serotonin transporter (SLC6A4) are associated with expression levels and susceptibility to anxiety-disorder [8]. Similarly, VNTR variation in the promoter of nitric oxide synthase 2 (NOS2) alter expression and is associated with diabetic retinopathy [9]. In these above examples, the phenotypically important VNTRs were located in promoters, but gene expression can also be affected by distantly located VNTR-based enhancers. For example, variable allele length of a 5′-VNTR of the human insulin gene (INS) are associated with gene expression levels both in vitro and in vivo, and predispose to, among others, insulin-dependent diabetes mellitus [10,11]. Importantly, the same VNTR region has also been found to affect the expression of another gene (IGF2), located downstream relative to INS [12]. These results provide an important proof of concept by showing that VNTRs with embedded enhancer properties can influence expression levels of distantly located genes (reviewed in [13]).

Structural changes in the genome (such as deletions, duplications/insertions, translocations, inversions and complex rearrangements) have been identified as a major type of inter-individual variation [14]. The best studied subset of structural changes, involving variation in the copy number DNA segments, are referred to as copy number variation (CNV). The rate of de novo formation for CNVs has been estimated to exceed the corresponding rate for single nucleotide polymorphisms (SNPs) [15,16]. Analyses of various types of human genetic variation performed hitherto are dominated by comparisons of different people. Little attention has been paid so far to analysis of acquired during lifetime differences between somatic cells from different tissues of the same person (i.e. post-zygotic variation, or mosaicism) [17]. The definition of post-zygotic variation is the presence of genetically distinct populations of somatic cells in an individual derived from a single zygote. The paucity of studies addressing post-zygotic genetic variation is remarkable, especially in view of the fact that many common disorders are apparently not a result of inheritance of defective allele(s) from the parents [18]. Reviews suggest that post-zygotic mosaicism is understudied and consequently underestimated [17,19,20,21,22]. Moreover, predictions indicate that the somatic variation must be widespread [23,24]. Given the high de novo mutation rates for chromosomal regions with CNVs and VNTRs, such loci should also be somatically variable and studies using monzygotic (MZ) twins, aging human cohorts and differentiated tissues point towards the importance of this aspect of human genetics [25,26,27,28].

We describe a somatically variable VNTR with a repeated motif of 32 bp on chromosome 21q22.11. This VNTR is located in a region containing four related cytokine receptor genes, namely IFNAR2, IL10Rb, IFNAR1 and IENG2. We show that this locus is somatically variable using cohorts of monzygotic twins as well as multiple tissues from single subjects and that it has sequence properties suggesting it to be an enhancer.

**Methods**

**Cohorts of studied subjects**

Blood samples from 63 pairs of monzygotic (MZ) twin pairs were studied. Of these, 22 MZ pairs were young (age 3–43) [28]. The remaining MZ twins were older than 60 years and derived from the Swedish Adoption Twin Study of Aging (SATSA) from the population-based Swedish Twin Registry [28]. Moreover, 21 patients with breast cancer were included, where we studied blood, primary tumor and normal breast tissue from the same affected breast.

**Ethics Statement**

The study is approved by the Regional Research Ethics Committee in Uppsala. The collections of human samples at all involved centers (Karolinska Institutet, Sweden; NIH, USA and Oncology Center, Bydgoszcz, Poland) have been approved by their respective Research Ethics Committees. Each studied adult subject has provided written informed consent. Written informed consent was obtained from the caretakers/guardians on the behalf of the minors/children that participated in this study.

**Illumina SNP genotyping**

All samples were genotyped on Illumina 610-array or 660W SNP arrays, representing a similar collection of probes (www.illumina.com/support/array/array_kits/human610-quad-beadchip_kit.ilmn and www.illumina.com/support/array/array_kits/human660w-quad-dna_analysis_kit.ilmn). Two-hundred nanogram of genomic DNA was genotyped using Illumina-human-610 and -660W arrays according to standard protocols [29], as previously described [28]. The results were analyzed for confirmation of monozygosity for each twin pair and for all samples from the same subject. The expected values for different tissues from the same person should be as genotypic concordance for monzygotic twins (>99.9% identical). We analyzed Illumina files by Nexus-Copy-Number program (BioDiscovery, CA, USA).

**Bioinformatic analysis of the locus between IL10Rβ and IFNAR1 genes**

The locus showing variation was analyzed for repeated elements with the RepeatMasker [30] and tools such as MREPS [31] and Tandem Repeats Finder [32]. Apart from describing the tandem repeat sequence, these analyses also defined non-repetitive regions in this locus that could be used for primer design and definition of alignment-anchors.

**Polymerase chain reaction using genomic DNA**

All PCRs were performed in 25 μl reactions comprising 10 ng gDNA, 0.4 mM each dNTP (Saveen Werner, Sweden), 2 mM MgCl2 (Invitrogen, Carlsbad, USA), 0.4 μl of primers 1 and 8 (primer 1, 5′-GCTAACAGCTGAGATTGCC-3′ and primer 8, 5′-CCATGGGTATCCGATCC-3′), 1× PCR buffer (Invitrogen) and 0.04 U/μl Platinum Taq DNA polymerase (Invitrogen). Phusion high-fidelity DNA polymerase (New England Biolabs; cat. No M0530L) was also used according to the manufacturer’s recommendations. The PCR products were analyzed on 1% agarose gel.

**TA cloning, plasmid purification**

For sub-cloning in pCR2.1-TOPO vector (Invitrogen), 2 μl of PCR product was used. Up to 50 clones per single PCR product were picked and cultured in LB medium containing 50 μg/ml kanamycin. The plasmids were purified using QIAprep miniprep (Qiagen, Hilden, Germany). To confirm the presence of insert, 500 ng of plasmids were digested with EcoRI enzyme (NEB, Ipswich, USA) and analyzed on 1% agarose gel.

**Sanger sequencing**

225 ng of plasmid DNA and 1.6 μM sequencing primer were used in 10 μl reactions with 4 μl BigDye® Terminator v3.1 (Applied Biosystems, Foster city, USA). Each sequencing reaction was done in triplicate on ABI 3730xl machine. Sequencing
primers were: primer 2, 5'-GAATCGCTTGAGCCCGGAAGG-3'; primer 3, 5'-CAGGGAGATCCGCTTGAAC-3'; primer 4, 5'-CCTGGGTAACACCGCGGAAATCC-3'; primer 5, 5'-GTGTTGGTGGACGACGAGATCG-3'; primer 6, 5'-ATACGTA-TATACTCAGTACT-3'; primer 7, 5'-TATACTCAGTACTATATT-3'; primer 8, 5'-TATATTCCATACT-3'; primer 9, 5'-GAATCGCTTGAACCCGGAAGG-3'.

The sequenced alleles are deposited in the GenBank (accession numbers JQ904024 through JQ904030). We implemented the Phrap-algorithm for accuracy of the assembly, as recommended for repeat-rich sequences. For a sequence to enter further analysis, at least one sequence-read had to go through both of the alignment-anchors (i.e. non-repeated flanking sequences), to avoid erroneous alignments. After alignment the 'compare contigs' option in the CodonCode-Aligner was used to compare the consensus sequences of the identified alleles.

Results

Analysis of tentative enhancer element and CpG islands

We used the Enhancer Element Locator (EEL) computer program [33] to identify suspected enhancer elements in the locus between the IL10Rb and IFNAR1 genes. Conserved non-coding elements (CNEs) were predicted by EEL-program using the JASPAR CNE matrix profiles [34,35]. This is a collection of 233 matrix profiles from human conserved non-coding elements for analysis of transcription factor binding sites (TFBS) and enhancer elements. TOMTOM Motif Comparison Tool was also used in analysis of the core sequence of the hypervariable region for similarities with known motifs for transcription factor binding [http://meme.nbcr.net/meme/cgi-bin/tomtom.cgi] [36]. To analyze the GC-content and predict CpG islands in the region we used the CpGPlot-software [http://www.ncbi.nlm.nih.gov/Tools/emboss/cpgplot/].

Illumina SNP genotyping suggests a post-zygotic and inter-individual variation in the locus between IL10Rb and IFNAR1

We initially genotyped blood DNA from 63 monozygotic (MZ) twin pairs using Illumina 610 or 660W SNP arrays. Twenty-two MZ pairs were genotyped using 610 array and 41 MZ pairs were genotyped using 660W SNP arrays and each MZ pair was treated as a single case for analysis of post-zygotic variation. Because nuclear genomes of MZ twins are identical at conception, they represent a good model for studying post-zygotic variation. The results were analyzed using Nexus-Copy-Number-Pro-software and the region between IL10Rb and IFNAR1 genes in 21q22.11 attracted our attention as it showed a frequent variation. Twenty eight out of 63 MZ twin pairs (44.4%) showed clear-cut differences in fluorescent intensity signal as measured by Log R ratio (LRR), either for two consecutive probes on 610-array (cnvi0010761 and cnvi0010761, at positions of 33615750 bp and 33616015 bp, respectively) or for two other adjacent probes on 660W-array (cnvi0065276 and cnvi0066475, at positions of 33615750 bp and 33616015 bp, respectively) (Fig. 1). For instance, the two probes on 610 array indicated deletion in this region in blood DNA of twin 012_02, when compared to its co-twin and the two probes on 660W-array indicated deletion in this region in blood DNA of twin 159201, compared to its co-twin (Fig. 1A and B).

We further expanded our study by 660W-array SNP genotyping of multiple tissues from 21 patients diagnosed with breast cancer, where peripheral blood, primary breast tumor, and healthy morphologically normal breast tissue from the breast affected with primary tumor were analyzed. Here we counted each patient as one case for analysis of post-zygotic variation. Clear differences
in LRR values were observed also in this cohort for two probes (cvi0066475 and cvi0065276) when comparing different tissues of the same patient in 13 out of 21 cases (61.9%) (Fig. 1C and D).

Thus, in summary for both cohorts of MZ twins and breast cancer patients, Illumina SNP beadchips suggested a post-zygotic mosaicism in 41 out of 84 (48.8%) cases, in the locus between IL10Rβ and IFNAR1 genes represented by the four consecutive array probes. Statistical analysis on this relatively limited sample size failed to reject the hypothesis of no association between cancer diagnosis and presence of post-zygotic mosaicism (not shown).

**Post-zygotic and inter-individual mosaicism of a presumptive enhancer embedded in a variable number of tandem repeats (VNTR)**

Application of repeat finding programs on the reference sequence encompassing locus between the IL10Rβ and IFNAR1 genes, revealed that the four above mentioned Illumina probes are located within a previously not characterized variable number of tandem repeats (VNTR) (Fig. 2). The NCBI reference sequence (build 36.3) displayed a 32 bp core motif repeated seven times in the center of the tandem repeat locus and this core was flanked by several similar sequence motifs (Fig. 2D, see HVR1098). This VNTR segment was further embedded in a region very rich in other types of common repeats (not shown), which made it challenging to design PCR- and sequencing-primers in the region around the VNTR segment. The primers that generated reliable results are shown in Figure 2C. The only primers that reproducibly generated a PCR product from genomic DNA were primers 1 and 8.

For the PCR-based validation of array results we selected a representative series of 17 cases where Illumina results suggested post-zygotic variation (Table 1, cases 1–17, Fig. 3, 4, 5). These encompass MZ twin pairs (9 cases) and samples from tissues of breast cancer patients (8 cases). The list of subjects taken for validation included also 7 additional samples from unrelated control subjects, where only one tissue was studied. We approached validation in this region by PCR amplification from genomic DNA with primers 1 and 8. This was followed by subcloning of the products into plasmids, preparation of plasmid DNA from 20–50 bacterial clones for each PCR reaction, analysis of inserts and Sanger sequencing using the plasmid DNA as template. It was apparent from the initial PCR reactions with primers 1 and 8 that there was a considerable variation in the length of amplified fragments. The sequencing was performed using primers 2 through 7 (Fig. 2) as well as with plasmid-based primers, using all subcloned fragments that were of different size, compared to the most common allele (see below). The sequence assembly was performed separately for each subcloned fragment and was guided by the use of anchor 1 (A1) and anchor 2 (A2) sequences (Fig. 2C and D), which were non-repetitive and located close to the cassette of tandem repeat motifs. The Sanger sequencing confirmed the variation and established nine fully sequenced alleles, with at least two high-quality forward and reverse sequence reads, showing sufficient overlap to assure the correct assembly across multiple similar sequence motifs. These sequences are deposited in the GenBank database (accession numbers JQ904024 through JQ904030). We named each of the alleles as HVR (for hypervariable region), followed by the number of nucleotides in the sequence between primers 1 and 8. Among the fully sequenced alleles, the most abundant one (HVR1098, allele frequency ~45%, Fig. 2D) was in agreement with the genome reference sequence. In addition to HVR1098, we established the full sequence for five longer alleles (HVR1157, HVR1162, HVR1187, HVR1219 and HVR1237) and three shorter (HVR1066, HVR842 and HVR800) (Fig. 2 and Table 1). However, the limits of current sequencing technology did not permit establishing of the full-length sequence for the five additional longer HVR alleles (based on the same stringent quality control of sequence reads that are aligned between anchors 1 and 2 segments) and their sizes were therefore estimated from agarose gels (Fig. 5). We also considered a possibility that the observed variation might be due to PCR artifacts. We addressed this by using different DNA polymerase with proof-reading activity. Selected samples (Fig. 5) were a subject to PCR amplification using (in addition to Taq polymerase) Phusion high-fidelity DNA polymerase starting from genomic DNA and the results showed the same pattern of post-zygotic variation.

It is noteworthy that we validated a relatively high percentage (10 out of 17; 58.8%) of cases that were suspected to contain post-zygotic genetic variation in the studied locus from the Illumina data. When extrapolated to all subjects included in our study, somatic variation in this VNTR locus is approximately 24%, which is a high number for a locus displaying post-zygotic variation, when compared with the literature [17]. We further calculated the total number of times, for all samples and all cases combined, that each of the 14 HVR-alleles occurred in our study (Fig. 4). The most common allele was HVR1098 that was fully sequenced and was in agreement with NCBI reference sequence. The second most common was HVR1700 and its full sequence still remains to be determined. Table 2 shows the summary of all cases, where Illumina data could be validated. To explain as to why the validation of Illumina results was unsuccessful for approximately 40% of cases, we analyzed the “probeA”-sequences that are used for synthesis of probes attached to beads and capture of genomic DNA on Illumina beadchips. Global genome BlastN searches for similarities of “probeA”-sequences for cnvi0010759, cnvi0010761, cnvi0065276 and cnvi0066475 showed that these are not unique (not shown), as they match to multiple regions in the human reference sequence and this is likely the reason for the not fully predictable behavior during genotyping. We presume that the results of Illumina copy number genotyping for these “probeA”-sequences is the sum of variation at the HVR region and possible variation that occurs in other regions of the genome with similarities to the “probeA”-sequences. This implies that the sole analysis of Illumina beadchip data from these four probes is not a sufficiently reliable tool for typing of the copy number status within the HVR in the locus between IL10Rβ and IFNAR1. Nevertheless, it was a good initial tool for variation detection.

The sequence of the segment between IL10Rβ and IFNAR1 was also analyzed using multiple bioinformatic tools for the content of functional elements important for gene transcription. We identified features suggesting that the HVR might influence gene transcription from this locus. The ELL-program found a clustering of suspected transcription factor binding sites approximately 4 kb upstream from IFNAR1 transcription start site, suggesting an enhancer. This presumptive enhancer element was overlapping with the hypervariable region (Fig. 3) and different alleles had different number of clusters with binding properties for transcription factors. Specifically, EEL program [33] identified similarity between HVR sequences and C00626.1 matrix profile [35] with the consensus sequence 5’-AATTGCTTCCAGATG-3’. This 15 bp sequence motif had 4 mismatches to the core of tandem repeat in the HVR sequences identified among the nine sequenced alleles. Using TOMTOM Motif Comparison Tool [36] we further analyzed 15 bp of our core HVR sequence (5’-TATTGGTTCCACATA), with or without additions of 5, 7 and 10 bases on both sides flanking the above sequence. From analyses of Jaspar database, four transcription factors of Saccharomyces cerevisiae
(RDR1, HAP2, OPI1 and HSF1) consistently showed the strongest scores. Results of the best match for the transcription factor RDR1 (for Repressor of Drug Resistance [37,38]) are shown in Fig. 3I. The RDR1 zinc cluster protein is a member of the Gal4p family of transcriptional regulators and its normal function in yeast is the transcriptional control of multidrug resistance.
Table 1. Size and distribution of 14 HVR-alleles identified by sequencing and gel electrophoresis.

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Subject ID</th>
<th>Tissue</th>
<th>HVR800</th>
<th>HVR842</th>
<th>HVR1066</th>
<th>HVR1098</th>
<th>HVR1157</th>
<th>HVR1187</th>
<th>HVR1162</th>
<th>HVR1219</th>
<th>HVR1237</th>
<th>HVR1400</th>
<th>HVR1550</th>
<th>HVR1650</th>
<th>HVR1700</th>
<th>Mosaic cases (no. of different alleles)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PF27*</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>SK58*</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>JM43*</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>KJ42*</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>PK6*</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>NM48*</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>KU25*</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>ML36*</td>
<td>BL</td>
<td>✓/×</td>
<td>•</td>
<td>✓/×</td>
<td></td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>159201**</td>
<td>BL</td>
<td>✓/×</td>
<td>•</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>004-01**</td>
<td>BL</td>
<td>✓/×</td>
<td>•</td>
<td>✓/×</td>
<td>✓/×</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>030-01**</td>
<td>BL</td>
<td>✓/×</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>148341**</td>
<td>BL</td>
<td>✓/×</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>212341**</td>
<td>BL</td>
<td>✓/×</td>
<td>•</td>
<td>•</td>
<td>✓/×</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>21801**</td>
<td>BL</td>
<td>•</td>
<td>✓/×</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Cont.

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Subject ID Tissue</th>
<th>HVR800</th>
<th>HVR842</th>
<th>HVR1066</th>
<th>HVR1098</th>
<th>HVR1157</th>
<th>HVR1187</th>
<th>HVR1162</th>
<th>HVR1219</th>
<th>HVR1237</th>
<th>HVR1400</th>
<th>HVR1550</th>
<th>HVR1650</th>
<th>HVR1700</th>
<th>Mosaic cases (no. of different alleles)</th>
</tr>
</thead>
<tbody>
<tr>
<td>21802**</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>15</td>
<td>183411A**</td>
<td>BL</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>16</td>
<td>188831**</td>
<td>BL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>17</td>
<td>169101A**</td>
<td>BL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>18</td>
<td>F1</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>19</td>
<td>M1</td>
<td>BL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Stan</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>01DM</td>
<td>BL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>22LG</td>
<td>BL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>25AK</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>PE129</td>
<td>BL</td>
<td>✓/×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The ✓/× indicate that the size of the allele was determined by both agarose gel images and sequencing, whereas filled circles (-) denote that the allele size was estimated from agarose gel images.

The two most common alleles (HVR1098 and HVR1700) are highlighted in bold and underlined text.

The sample indicated by a single asterisk (*) are from breast cancer patients. BL, PT and UM indicate peripheral blood DNA, primary breast tumor and healthy morphologically normal breast tissue from a patient affected with breast cancer, respectively.

The samples indicated by two asterisks (**) are monozygotic twin pairs.

doi:10.1371/journal.pone.0067752.t001
revealed strongest match to the mouse transcription factor Foxg1 binding motif (Fig. 3J). Forkhead-box (FOX) family of transcription factors represent a large group of proteins with crucial roles in development and metabolism, which were studied in many species. The human genome encodes 43 FOX proteins [40,41,42]. The FOXG1 is crucial for normal brain development [43] and loss-of-function mutations in FOXG1 cause an atypical form of Rett syndrome [44]. On the other hand, overexpression of FOXG1 is implicated in cancer development [45,46]. In summary, the motif analyses suggest that the HVR locus might function as an enhancer but we have not unambiguously identified its protein binding partners. Further studied are needed to address this question.

Furthermore, mining of the ENCODE dataset [1] (http://genome.ucsc.edu/ENCODE/) supported a role for the 1.45 kb region (displayed in Fig. 2G) as a suspected enhancer element upstream from the transcription start site of the IFNAR1 gene on chromosome 21, showing a clustering of TFBSs in the core of the HVR. Grey boxes indicate the positions of the predicted TFBSs in the region and they were determined by the CN0062.1 matrix profile (from ref. [35]) with the consensus sequence 5’-AATTGCTTCCAGATG. The predicted TFBSs in sequenced alleles HVR1219, HVR1187, HVR1162, HVR1157, HVR1098, HVR1066 and HVR842, identified using the matrix profile CN0062.1. Panel I shows results of the best match for Saccharomyces cerevisiae transcription factor RDR1 (for Repressor of Drug Resistance 1) with TOMTOM Motif Comparison Tool [36]. Panel J illustrates TOMTOM-based analyses of mouse and human database of transcription factor binding sites [39], which revealed the best match to the mouse transcription factor Foxg1 binding motif.

doi:10.1371/journal.pone.0067752.g003

Figure 3. Analysis of the transcription factor binding sites (TFBSs) for the sequenced HVR-alleles. Panel A shows graphical representation of the most frequently occurring allele in our data set (HVR1098) with identical distribution of in-dels as compared to the NCBI reference genome build 36.3 (see also Fig. 2B–D). The HVR region is flanked by the non-repetitive sequences referred to as anchor A1 and A2 (yellow boxes) that were used for alignment of sequence reads. Green box illustrates the position of a CpG island and the overall layout of this figure is analogous to Fig. 2. Analysis using the EEL-software (Enhancer Element Locator [33]) of –1.2 kb of the NCBI reference sequence upstream from the transcription start site of the IFNAR1 gene on chromosome 21, showing a clustering of TFBSs in the core of the HVR. Grey boxes indicate the positions of the predicted TFBSs in the region and they were determined by the CN0062.1 matrix profile (from ref. [35]) with the consensus sequence 5’-AATTGCTTCCAGATG. Panels B–H show the predicted TFBSs in sequenced alleles HVR1219, HVR1187, HVR1162, HVR1157, HVR1098, HVR1066 and HVR842, identified using the matrix profile CN0062.1. Panel I shows results of the best match for Saccharomyces cerevisiae transcription factor RDR1 (for Repressor of Drug Resistance 1) with TOMTOM Motif Comparison Tool [36]. Panel J illustrates TOMTOM-based analyses of mouse and human database of transcription factor binding sites [39], which revealed the best match to the mouse transcription factor Foxg1 binding motif.

doi:10.1371/journal.pone.0067752.g003
the predicted enhancer element (Figs. 2 and 3). Thus, in summary, the above observations suggest a functional gene-regulatory role of the studied locus and that the VNTR we describe should be studied further for functional consequences on gene transcription.

**Discussion**

Post-zygotic variation has been estimated to ~1% in young subjects routinely analyzed in the course of genetic counseling [47]. Our recent analyzes in population-based aging cohort showed that ~3.5% of people older than 60 years carry mega-base range post-zygotic rearrangements [28]. Our current results suggest that the VNTR locus studied here has a considerably higher rate of post-zygotic variation, as ~24% of cases in this study have been estimated to display post-zygotic differences. Furthermore, this number is likely an underestimate, as a limited number of specimens from different tissues were studied for each case. These results are in agreement with the estimates suggesting that *de novo* mutation rate for VNTRs is higher than the corresponding rates for other types of structural rearrangements [2]. The inter-individual copy number variation in the VNTR locus studied here has been noticed previously, but was not explored in detail [14] (supplemental data; locus ID CNVR7995). Conrad et al. 2010 applied two variation detection methods; first was Nimblegen genotyping on 42M genome-wide tiling-path array. Results from this array were validated by 105K Agilent array designed to target the variable loci only. The CNVR7995 in Conrad et al. is one among 8599 inter-individually variable loci. Although CNVR7995 was shown variable among different people, it could not be unambiguously genotyped by further array-CGH experiments using 450 subjects; i.e. placed in a one class of genotypes and were not possible to score unambiguously. The intriguing question emerging from the above reasoning is: Are the remaining loci (39%, 3360 loci that could not be unambiguously genotyped on the final validation platform in Conrad et al. 2010) also showing post-zygotic variation?

One of the first described and well-studied VNTR-based enhancers in the human genome is located upstream of the human insulin gene (*INS*) on chromosome 11p15. This VNTR has been shown to regulate not only the expression of the closest gene (*INS*), but also the *IGF2* gene, located downstream on the same DNA strand from *INS*, thus demonstrating the long range effect of the VNTR on gene transcription [12,48]. The field of DNA enhancers provides additional examples regarding a capacity of the enhancers to exert their regulatory effects on genes located at large genomic distances. Enhancers can activate gene expression independent of their orientation and are commonly scattered across noncoding intervals, in extreme cases functioning at a distance of >1 Mb from their gene promoter target [13,49]. The VNTR upstream of the *INS* gene has also attracted a considerable interest in medical genetics, as its length has been associated with type 1 and type 2 diabetes, latent autoimmune diabetes in adults (LADA), polycystic ovary syndrome as well as with size at birth [50,51,52,53,54].

The region around the presumptive enhancer studied here (Fig. 2) contains four functionally related receptor genes: interferon alpha, beta and omega receptor 2 (*IFNAR2*); interleukin 10 receptor beta (*IL10Rb*); interferon alpha, beta and omega receptor 1 (*IFNAR1*); and interferon gamma receptor 2 (*IFNGR2*). Considering the above discussed regulatory functions for VNTR upstream of the *INS* gene and other well studied enhancers, it is reasonable to hypothesize that this tentative VNTR-based enhancer located between *IL10Rb* and *IFNAR1* genes might be involved in regulation of transcription of not only *IFNAR1* gene, but also additional genes located in its vicinity. This issue is an important subject for future studies. There exists an extensive literature describing physiological functions for these interferon/
cytokine receptor pathways and their involvement in disease-related processes [53,56,57,58,59]. For instance, type-I interferon (IFN-alpha)-induced signaling was reduced in T cells and B cells from 3 major groups of cancer patients (breast cancer, melanoma, and gastrointestinal cancer) compared to healthy controls. Type-II interferon (IFN-gamma)-induced signaling was also reduced in B cells from these cancer patient groups. These findings suggest that defects in lymphocyte IFN signaling arise in patients with common cancers, and these defects may represent a common cancer-associated mechanism of immune dysfunction [56]. Interferon alpha is also implicated in the autoimmune disease such as systemic lupus erythematosus, where there is a continuous overproduction of IFN-alpha and increased expression of IFN-alpha-regulated genes [60].

**Conclusions**

This study shows post-zygotic genetic variation in a VNTR-locus, which has sequence properties of an enhancer. This variation may affect the expression of gene(s) that are under the control of this regulatory element and understanding the phenotypic consequences of both post-zygotic and inter-individual variation becomes critical.
variation within this enhancer on the level of single cell and whole organism is a task for future work. Our findings of post-zygotic genetic variation add another level of complexity to the genetic variation among VNTR loci in general and in particular to the possible phenotypic consequences of variation in the VNTR-locus between IL10Rβ and IFNAR1 genes. This VNTR-based presumptive enhancer is within a locus containing four functionally related cytokine receptor genes; IFNAR2, IL10Rβ, IFNAR1 and IFNGR2. We hypothesize that this element might function in transcriptional regulation of not only the closest IFNAR1 gene, but also other flanking genes. The extension of our work may unveil the normal function of this VNTR-locus in transcriptional control of genes. Furthermore, our work opens up for studies of associations of length of VNTR alleles in cohorts of patients with various immune system dysfunctions, for instance autoimmune disorders or cancer. Interferons, acting via multiple receptor genes encoded from the locus studied here, are already used in clinical treatment of patients with various conditions. Our study may also be a starting point for analysis aiming at understanding of why there often is a variable response to treatment with interferons.

Supporting Information

Figure S1 The results from mining of the Encode project dataset (http://genome.ucsc.edu/ENCODE/). Panel A shows ~1.3 kb segment centered on HVR with coordinates chr21:34687376-34700434 (build 37/hg19) and chr21:33609246-33622304, acc. to build 36/hg18. On the right hand side, this view also includes the promoter/cis-regulatory elements and exon 1 of the IFNAR1 gene. The three colored solid horizontal bars show results (in compressed view) from the ChIP-seq experiments in six cell lines. These were analyzed by a combination of the ChromHMM and Segway programs to perform the segmentations. Three cell lines (GM12878, HeLa-S3 and HepG2) showed “predicted weak enhancer or open chromatin cis regulatory element” in yellow. Other color codes indicate: bright red, predicted promoter region including transcription start site; light red, predicted promoter flanking region; dark green, predicted transcribed region; gray, predicted repressed or low activity region; light green, low activity region. Results from ENCODE data tracks representing the open chromatin signals based on DNase-seq experiments are shown below. Light blue bars indicate DNaseI hypersensitivity clusters in CD20+ cells, GM18507 cells, HA-sp cells, HCFaa cells and HCM cells. Panel B illustrates ENCODE data in greater detail for a segment of 1.45 kb, which corresponds to the region displayed in Fig. 2C (chr21:34693180-34694630, build 37/hg19) and chr21:33615050-33616500, build 36/hg18). The results from ChIP-seq experiments and data tracks representing the open chromatin signals based on DNase-seq experiments are shown in expanded view. The color codes for different predictions are the same as described above for panel A.

Table 2. Summary of validation of somatic variation in the IFNAR1 locus.

<table>
<thead>
<tr>
<th>Subject ID</th>
<th>Analysed tissues</th>
<th>Mosaicism indicated by illumina platform?</th>
<th>Illumina results verified?</th>
<th>Validation method</th>
</tr>
</thead>
<tbody>
<tr>
<td>SK58*</td>
<td>BL, UM, PT</td>
<td>Yes</td>
<td>Yes</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>ML36*</td>
<td>BL, UM, PT</td>
<td>Yes</td>
<td>Yes</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>K42*</td>
<td>BL, UM</td>
<td>Yes</td>
<td>No</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>NM48*</td>
<td>BL, UM, PT</td>
<td>Yes</td>
<td>No</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>KU25*</td>
<td>BL, UM, PT</td>
<td>Yes</td>
<td>No</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>PF27*</td>
<td>BL, UM, PT</td>
<td>Yes</td>
<td>No</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>JM43*</td>
<td>BL, UM, PT</td>
<td>Yes</td>
<td>No</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>PK6*</td>
<td>BL, UM, PT</td>
<td>Yes</td>
<td>No</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>004_01/004_02**</td>
<td>BL</td>
<td>Yes</td>
<td>Yes</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>159201/159202**</td>
<td>BL</td>
<td>Yes</td>
<td>Yes</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>21801/21802**</td>
<td>BL</td>
<td>Yes</td>
<td>Yes</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>183411A/183412A**</td>
<td>BL</td>
<td>Yes</td>
<td>Yes</td>
<td>Gel</td>
</tr>
<tr>
<td>148341/148342**</td>
<td>BL</td>
<td>Yes</td>
<td>Yes</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>169101A/169102A**</td>
<td>BL</td>
<td>Yes</td>
<td>Yes</td>
<td>Gel</td>
</tr>
<tr>
<td>188831/188832**</td>
<td>BL</td>
<td>Yes</td>
<td>Yes</td>
<td>Gel</td>
</tr>
<tr>
<td>2123411/2123412**</td>
<td>BL</td>
<td>Yes</td>
<td>Yes</td>
<td>Gel+Seq</td>
</tr>
<tr>
<td>030_01/030_02**</td>
<td>BL</td>
<td>Yes</td>
<td>No</td>
<td>Gel+Seq</td>
</tr>
</tbody>
</table>

Summary of Illumina SNP genotyping, which suggested structural variation within the hypevariable region and results from subsequent confirmation using Sanger sequencing and agarose gel electrophoresis. One (*) and two (**) asterisks after the subject ID indicate patients with breast cancer and pairs of monozygotic twins, respectively. BL, UM and PT stand for DNA from peripheral blood cells, healthy morphologically normal breast tissue from a patient affected with breast cancer and primary breast tumor, respectively. "Seq" indicate that the somatic mosaicism was verified by Sanger sequencing while "Gel" shows that it was confirmed by estimation of allele sizes from agarose gel.

doi:10.1371/journal.pone.0067752.t002

Acknowledgments

We thank Kimmo Palin for methodological advice, Lars Feuk for fruitful discussions and Ian Dunham for advice on mining Encode dataset.

Author Contributions

Conceived and designed the experiments: JPD LAF HRR. Performed the experiments: DA HRR KRP SP HP AZ. Analyzed the data: LAF HRR JPD. Contributed reagents/materials/analysis tools: MPW NLP TPO LGR FWM ES MJ WZ AP. Wrote the paper: JPD LAF HRR.
References


